Clinical trial
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, Followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
NCT05006352 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, Followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
- Lead sponsor
- Denali Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 11, 2021
- Completion date
- June 5, 2024
- Enrollment
- 29 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.